2025
RAS(ON) Therapies on the Horizon to Address KRAS Resistance: Highlight on a Phase III Clinical Candidate Daraxonrasib (RMC-6236)
Ma Z, Zhou M, Shen Q, Zhou J.
Show affiliations
- Ma Z — Chemical Biology Program, Department of Pharmacology and Toxicology, University of Texas Medical Branch (UTMB), Galveston, Texas 77555, United States.
- Zhou M — Chemical Biology Program, Department of Pharmacology and Toxicology, University of Texas Medical Branch (UTMB), Galveston, Texas 77555, United States.
- Shen Q — Department of Interdisciplinary Oncology, School of Medicine, LSU LCMC Health Cancer Center, Louisiana State University Health Sciences Center, New Orleans, Louisiana 70112, United States.
- Zhou J — Chemical Biology Program, Department of Pharmacology and Toxicology, University of Texas Medical Branch (UTMB), Galveston, Texas 77555, United States.
1 read0 want to read
Most-cited papers citing this
- Signal Transduct Target Ther · 2026 · cited by 24
- Molecules · 2026 · cited by 6
- Exp Hematol Oncol · 2026 · cited by 2
- Drugs · 2026 · cited by 2
- J Med Chem · 2026
Log in to like, log, and share thoughts on this paper.
Discussion
Share your thoughts above to start a thread. Constructive feedback only — reply to and like others’ posts.
No discussion yet — be the first to share constructive thoughts.